Assay development for point-of-care COVID-19 antibody detection

A key requirement for returning to societal and economic normality is the evaluation and surveillanceof SARS-CoV-2 infection and immunity. The proposed technologies described herein, enable a safe and effectivediagnostic test that can quickly provide an easily interpreted result for SARS-CoV-2 immunity, all without complicated equipment, expensive reagents, or high-level biosafety containment facilities. Such a system would allow for rapid testing in decentralized labs or at point-of-care providing quick data information on antibody responses produced by infection or vaccination. This data will be invaluable for assessing the most efficacious SARS-CoV-2 vaccine(s) for use in population-wide vaccination booster campaigns against currently circulating strains, and will also guide future public health mitigation strategies to reduce the spread of viral transmission.

Faculty Supervisor:

Dustin Little;Marc Adler

Student:

Partner:

OxiLight

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Toronto Metropolitan University

Program: